Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of semaglutide injection vs Wegovy in Chinese adults with obesity
CTR20244724Phase 3Completed
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Dec 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20244724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244724.